DiaMedica Therapeutics (DMAC) Shares Outstanding (Weighted Average) (2018 - 2026)

DiaMedica Therapeutics has reported Shares Outstanding (Weighted Average) for 9 years, with the latest figure at $53.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 25.56% year-over-year to $53.8 million; the trailing twelve-month figure through Mar 2026 stood at $53.8 million (up 25.56% YoY), and the FY2025 full-year result was $47.0 million, up 16.28% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $53.8 million, up from $47.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $53.8 million in Q1 2026, with the low at $26.4 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $36.1 million across 5 years, with a median of $38.0 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) gained 0.02% — and 2024, when it jumped 43.51%.
• DiaMedica Therapeutics' Shares Outstanding (Weighted Average) stood at $26.4 million in 2022, then rose by 23.16% to $32.6 million in 2023, then grew by 24.07% to $40.4 million in 2024, then grew by 16.28% to $47.0 million in 2025, then grew by 14.5% to $53.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $53.8 million (Q1 2026), $47.0 million (Q4 2025), and $45.2 million (Q3 2025), per Business Quant data.